JP2020512350A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512350A5 JP2020512350A5 JP2019553055A JP2019553055A JP2020512350A5 JP 2020512350 A5 JP2020512350 A5 JP 2020512350A5 JP 2019553055 A JP2019553055 A JP 2019553055A JP 2019553055 A JP2019553055 A JP 2019553055A JP 2020512350 A5 JP2020512350 A5 JP 2020512350A5
- Authority
- JP
- Japan
- Prior art keywords
- indazole
- carboxamide
- phenyl
- composition according
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 31
- 238000000634 powder X-ray diffraction Methods 0.000 claims 24
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims 19
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 14
- 239000013078 crystal Substances 0.000 claims 9
- 229950004288 tosilate Drugs 0.000 claims 8
- 150000008064 anhydrides Chemical class 0.000 claims 7
- 150000004682 monohydrates Chemical class 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000000126 substance Substances 0.000 claims 6
- 239000003960 organic solvent Substances 0.000 claims 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- 238000004566 IR spectroscopy Methods 0.000 claims 1
- 238000001069 Raman spectroscopy Methods 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000002274 desiccant Substances 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- -1 monohydrate salt Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762477411P | 2017-03-27 | 2017-03-27 | |
| US62/477,411 | 2017-03-27 | ||
| PCT/US2018/024603 WO2018183354A1 (en) | 2017-03-27 | 2018-03-27 | Niraparib compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020512350A JP2020512350A (ja) | 2020-04-23 |
| JP2020512350A5 true JP2020512350A5 (enExample) | 2021-05-06 |
Family
ID=63676949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553055A Pending JP2020512350A (ja) | 2017-03-27 | 2018-03-27 | ニラパリブ組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11091459B2 (enExample) |
| EP (1) | EP3600314A1 (enExample) |
| JP (1) | JP2020512350A (enExample) |
| KR (1) | KR20200014736A (enExample) |
| CN (1) | CN110944638A (enExample) |
| AU (2) | AU2018246214B2 (enExample) |
| BR (1) | BR112019020211A2 (enExample) |
| CA (1) | CA3058375C (enExample) |
| EA (1) | EA201992177A1 (enExample) |
| IL (1) | IL269630A (enExample) |
| MX (1) | MX2019011496A (enExample) |
| SG (1) | SG11201909011PA (enExample) |
| TW (1) | TWI761476B (enExample) |
| WO (1) | WO2018183354A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201811564QA (en) | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| EP3600314A1 (en) | 2017-03-27 | 2020-02-05 | Tesaro, Inc. | Niraparib compositions |
| CN118271233A (zh) | 2017-04-24 | 2024-07-02 | 特沙诺有限公司 | 尼拉帕利的制造方法 |
| US12156872B2 (en) | 2017-05-09 | 2024-12-03 | Tesaro, Inc. | Combination therapies for treating cancer |
| CA3063715A1 (en) | 2017-05-18 | 2018-11-22 | Tesaro, Inc. | Combination therapies for treating cancer |
| CA3076907A1 (en) | 2017-09-26 | 2019-04-04 | Tesaro, Inc. | Niraparib formulations |
| CN111372607A (zh) | 2017-09-30 | 2020-07-03 | 特沙诺有限公司 | 用于治疗癌症的联合疗法 |
| US11801240B2 (en) | 2017-10-06 | 2023-10-31 | Tesaro, Inc. | Combination therapies and uses thereof |
| CA3090479A1 (en) | 2018-02-05 | 2019-08-08 | Tesaro, Inc | Pediatric niraparib formulations and pediatric treatment methods |
| WO2020072796A1 (en) | 2018-10-03 | 2020-04-09 | Tesaro, Inc. | Crystalline forms of niraparib freebase |
| WO2020072860A1 (en) | 2018-10-05 | 2020-04-09 | Johnson Matthey Public Limited Company | Niraparib solid state form |
| CA3087392A1 (en) | 2019-07-16 | 2021-01-16 | Apotex Inc. | Crystalline forms of niraparib tosylate |
| UY39204A (es) * | 2020-05-08 | 2021-11-30 | Janssen Pharmaceutica Nv | Formulaciones farmacéuticas de acetato de abiraterona y niraparib |
| MX2024000949A (es) | 2021-07-19 | 2024-02-08 | Janssen Pharmaceutica Nv | Tratamiento de cancer de prostata metastasico resistente a la castracion con niraparib. |
| CN119156216A (zh) | 2022-02-15 | 2024-12-17 | 特沙诺有限公司 | 尼拉帕尼用于治疗脑癌的用途 |
| WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
| EP4532493A1 (en) | 2022-06-01 | 2025-04-09 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof |
| WO2024238587A1 (en) | 2023-05-17 | 2024-11-21 | Tesaro, Inc. | Novel use of an inhibior of the a poly-adp ribose polymerase (parp) in the treatment of cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2647545C (en) | 2006-04-03 | 2016-02-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
| GB0606663D0 (en) | 2006-04-03 | 2006-05-10 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| WO2008043024A2 (en) | 2006-10-04 | 2008-04-10 | Kalypsys, Inc. | Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease |
| EP2805945B1 (en) | 2007-01-10 | 2019-04-03 | MSD Italia S.r.l. | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
| JP5593229B2 (ja) * | 2007-10-17 | 2014-09-17 | クドス ファーマシューティカルズ リミテッド | ４−［３−（４−シクロプロパンカルボニル−ピペラジン−１−カルボニル）−４−フルオロ−ベンジル］−２ｈ−フタラジン−１−オン |
| JP5989965B2 (ja) | 2008-01-08 | 2016-09-07 | メルク シャープ エンド ドーム リミテッド | ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩 |
| US20100278921A1 (en) | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| CN102482282A (zh) * | 2009-08-26 | 2012-05-30 | 赛福伦公司 | 多环化合物的新形式 |
| CA2779052A1 (en) | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Pharmaceutical composition of entecavir and process of manufacturing |
| US9738915B2 (en) | 2012-12-07 | 2017-08-22 | Merck Sharp & Dohme Corp. | Biocatalytic transamination process |
| US9580407B2 (en) | 2012-12-07 | 2017-02-28 | Merck Sharp & Dohme Corp. | Regioselective N-2 arylation of indazoles |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| US9191894B2 (en) * | 2013-07-23 | 2015-11-17 | Disney Enterprises, Inc. | Power saving for multi-hop communications |
| CA2935857C (en) | 2014-01-05 | 2020-12-15 | Washington University | Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor |
| JP6500037B2 (ja) | 2014-04-22 | 2019-04-10 | キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ | 二環式ピラゾロン化合物および使用方法 |
| US10238630B2 (en) | 2014-05-28 | 2019-03-26 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer |
| DK3182975T3 (da) | 2014-08-22 | 2025-10-20 | Pharma& Schweiz Gmbh | Tabletter med høj doseringsstyrke af rucaparib |
| EP3230472A4 (en) | 2014-12-08 | 2018-06-13 | Myriad Genetics, Inc. | Methods and materials for predicting response to niraparib |
| DK3954690T3 (da) | 2015-07-02 | 2023-06-06 | Acerta Pharma Bv | Faste former og formuleringer af (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamid |
| SG11201811564QA (en) | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| CN106496187A (zh) * | 2016-09-14 | 2017-03-15 | 陕西科技大学 | 一种制备PARP抑制剂Niraparib的合成方法 |
| CN106831708A (zh) | 2016-11-22 | 2017-06-13 | 西安泰科迈医药科技股份有限公司 | 一种新型口服抗癌药物Nirapairb的合成方法 |
| CN108201537A (zh) | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种尼拉帕尼缓控释药物组合物及其用途 |
| CN106854176A (zh) | 2016-12-21 | 2017-06-16 | 南京艾德凯腾生物医药有限责任公司 | 一种制备尼拉帕尼对甲苯磺酸盐一水合物的方法 |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| EP3600314A1 (en) | 2017-03-27 | 2020-02-05 | Tesaro, Inc. | Niraparib compositions |
| BR112019020191A2 (pt) | 2017-03-27 | 2020-04-22 | Tesaro Inc | formulações de niraparib |
| CN118271233A (zh) | 2017-04-24 | 2024-07-02 | 特沙诺有限公司 | 尼拉帕利的制造方法 |
| US12156872B2 (en) | 2017-05-09 | 2024-12-03 | Tesaro, Inc. | Combination therapies for treating cancer |
| CA3063715A1 (en) | 2017-05-18 | 2018-11-22 | Tesaro, Inc. | Combination therapies for treating cancer |
| CN108530425A (zh) | 2017-05-27 | 2018-09-14 | 广州科锐特生物科技有限公司 | 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法 |
| CA3076907A1 (en) | 2017-09-26 | 2019-04-04 | Tesaro, Inc. | Niraparib formulations |
| CN111372607A (zh) | 2017-09-30 | 2020-07-03 | 特沙诺有限公司 | 用于治疗癌症的联合疗法 |
| US11801240B2 (en) | 2017-10-06 | 2023-10-31 | Tesaro, Inc. | Combination therapies and uses thereof |
| EP3731866A1 (en) | 2017-12-27 | 2020-11-04 | Tesaro Inc. | Methods of treating cancer |
| CA3090479A1 (en) | 2018-02-05 | 2019-08-08 | Tesaro, Inc | Pediatric niraparib formulations and pediatric treatment methods |
| WO2020072796A1 (en) * | 2018-10-03 | 2020-04-09 | Tesaro, Inc. | Crystalline forms of niraparib freebase |
| CA3087392A1 (en) * | 2019-07-16 | 2021-01-16 | Apotex Inc. | Crystalline forms of niraparib tosylate |
-
2018
- 2018-03-27 EP EP18774912.2A patent/EP3600314A1/en not_active Withdrawn
- 2018-03-27 KR KR1020197031668A patent/KR20200014736A/ko not_active Ceased
- 2018-03-27 TW TW107110575A patent/TWI761476B/zh active
- 2018-03-27 SG SG11201909011P patent/SG11201909011PA/en unknown
- 2018-03-27 JP JP2019553055A patent/JP2020512350A/ja active Pending
- 2018-03-27 CA CA3058375A patent/CA3058375C/en active Active
- 2018-03-27 AU AU2018246214A patent/AU2018246214B2/en active Active
- 2018-03-27 MX MX2019011496A patent/MX2019011496A/es unknown
- 2018-03-27 CN CN201880033357.6A patent/CN110944638A/zh active Pending
- 2018-03-27 BR BR112019020211-0A patent/BR112019020211A2/pt not_active Application Discontinuation
- 2018-03-27 WO PCT/US2018/024603 patent/WO2018183354A1/en not_active Ceased
- 2018-03-27 EA EA201992177A patent/EA201992177A1/ru unknown
-
2019
- 2019-09-25 IL IL26963019A patent/IL269630A/en unknown
- 2019-09-26 US US16/584,401 patent/US11091459B2/en active Active
-
2021
- 2021-06-04 US US17/339,896 patent/US11673877B2/en active Active
- 2021-10-08 AU AU2021245223A patent/AU2021245223A1/en not_active Abandoned
-
2023
- 2023-05-01 US US18/310,238 patent/US20230416223A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020512350A5 (enExample) | ||
| ES2380297T3 (es) | Hidrocloruro de nalmefeno dihidrato | |
| Mulye et al. | Improvement in physicochemical properties of ezetimibe using a crystal engineering technique | |
| CN102639531B (zh) | 噻托溴铵的无水合物 | |
| CN104797566A (zh) | 沃替西汀氢溴酸盐的新结晶形式 | |
| JP5184511B2 (ja) | 新しい結晶形態のラミブジン | |
| CN1970547B (zh) | 非布司他的晶型及其制备方法 | |
| JP2009534373A5 (enExample) | ||
| WO2018184185A1 (zh) | 奥扎莫德加成盐晶型、制备方法及药物组合物和用途 | |
| JP2023103328A (ja) | ビランテロールトリフェニル酢酸塩の新規な結晶形態及びこれらの調製プロセス | |
| RU2607515C2 (ru) | Кристаллическая форма натриевой соли 4-трет-бутил-n-{ 4-хлор-2-(1-окси-пиридин-4-карбонил)-фенил} -бензолсульфонамид | |
| CN103965116A (zh) | 半5-氟胞嘧啶盐、其制备方法及应用 | |
| WO2006057397A1 (ja) | （ｓ）－（－）－１－（４－フルオロイソキノリン－５－イル）スルホニル－２－メチル－１，４－ホモピペラジン塩酸塩・二水和物 | |
| JP2012512145A (ja) | フリバンセリンの結晶性の塩形態 | |
| BR112014001530B1 (pt) | Formas polimórficas do sal de sódio de 4-terc-butiln-[4-cloro-2-(1-óxi-piridina-4-carbonil)- fenil]-benzeno sulfonamida, composição farmacêutica e método de produção da mesma | |
| CA2767992A1 (en) | 2 - [[[2 -[(hydroxyacetyl) amino]- 4 -pyridinyl] methyl] thio]- n -[4 - (trifluoromethoxy) phenyl]- 3 -pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof | |
| PT2838892T (pt) | Forma sólida isolada de monocloridrato de anamorelina com baixa razão molar cloreto:anamolerina e baixo teor de solvente orgânico residual | |
| CN105646353B (zh) | 塞来昔布厄贝沙坦共无定形物 | |
| JP2010540440A5 (enExample) | ||
| CN102351784B (zh) | 一种盐酸贝尼地平晶型及其应用 | |
| JP2016533361A (ja) | ピラゾロピリジン化合物の固体形態 | |
| TW201917117A (zh) | 一種炔基吡啶類脯胺醯羥化酶抑制劑的晶型及其製備方法 | |
| CN102093309B (zh) | 非布司他的晶型及其制备方法 | |
| CN115536654A (zh) | 小檗碱橙皮素盐晶型及其制备方法和其组合物与应用 | |
| JP5265876B2 (ja) | アンドラストの新規で安定な結晶構造体 |